1-(3-Methoxybenzoyl)-4-phenylpiperazine | 333349-79-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(3-Methoxybenzoyl)-4-phenylpiperazine
• 英文别名: (3-methoxyphenyl)-(4-phenylpiperazin-1-yl)methanone
• CAS: 333349-79-4
• 化学式: C₁₈H₂₀N₂O₂
• mdl: MFCD01216327
• 分子量: 296.369
• InChiKey: NVKQYRYUTSGRIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3-Methoxybenzoyl)-4-phenylpiperazine 在 三氟二甲基硫醚络合物 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (3-hydroxyphenyl)(4-phenylpiperazin-1-yl)methanone
  参考文献：
  名称：

  Addressing cytotoxicity of 1,4-biphenyl amide derivatives: Discovery of new potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors

  摘要：

  Four different classes of new 17 beta-hydroxysteroid dehydrogenase type 2 (17 beta-HSD2) inhibitors were synthesized, in order to lower the cytotoxicity exhibited by the lead compound A, via disrupting the linearity and the aromaticity of the biphenyl moiety. Compounds 3, 4, 7a and 8 displayed comparable or better inhibitory activity and selectivity, as well as a lower cytotoxic effect, compared to the reference compound A. The best compound 4 (IC50 = 160 nM, selectivity factor = 168, LD50 approximate to 25 mu M) turned out as new lead compound for inhibition of 17 beta-HSD2. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.11.047
• 作为产物：
  描述：

  N-苯基哌嗪 、 间甲氧基苯甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 1-(3-Methoxybenzoyl)-4-phenylpiperazine
  参考文献：
  名称：

  Addressing cytotoxicity of 1,4-biphenyl amide derivatives: Discovery of new potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors

  摘要：

  Four different classes of new 17 beta-hydroxysteroid dehydrogenase type 2 (17 beta-HSD2) inhibitors were synthesized, in order to lower the cytotoxicity exhibited by the lead compound A, via disrupting the linearity and the aromaticity of the biphenyl moiety. Compounds 3, 4, 7a and 8 displayed comparable or better inhibitory activity and selectivity, as well as a lower cytotoxic effect, compared to the reference compound A. The best compound 4 (IC50 = 160 nM, selectivity factor = 168, LD50 approximate to 25 mu M) turned out as new lead compound for inhibition of 17 beta-HSD2. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.11.047

文献信息

• [EN] ARYLAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES ASSOCIATED WITH SERCA ACTIVITY<br/>[FR] PROCÉDÉS DE TRAITEMENT DE MALADIES ASSOCIÉES À LA MODULATION DE SERCA
  申请人：CELLADON CORP

  公开号：WO2010088450A3

  公开（公告）日：2010-12-23
• [EN] METHODS FOR TREATING DISEASES ASSOCIATED WITH THE MODULATION OF SERCA<br/>[FR] PROCÉDÉS DE TRAITEMENT DE MALADIES ASSOCIÉES À LA MODULATION DE SERCA
  申请人：CELLADON CORP

  公开号：WO2010088450A2

  公开（公告）日：2010-08-05

  Provided herein are compounds, compositions, and methods for treating or ameliorating diseases associated with the modulation of SERCA.